Top Banner

of 10

Dean Hartley: Alzheimer’s Association Research Initiatives

Oct 29, 2015

Download

Documents

Down Syndrome-Alzheimer's Disease Panel Presentation at Global Down Syndrome Foundation Research & Medical Care Roundtable on Thursday, July 18, 2013, at Children's Hospital Colorado. Dean Hartley, PhD, is Director of Science Initiatives, Medical and Scientific Relations, Alzheimer’s Association
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
  • 1

    Alzheimers Association Research Initiatives

    Dean M. Hartley, Ph.D. Director of Scientific Director

    Alzheimers Association

  • 2

    Our vision is a world without Alzheimers disease

    Our goals: Advance research Provide care

    and support Increase Concern &

    Awareness Public Policy &

    Advocacy Efforts

  • 3

    Alzheimers Association is the global leader in Alzheimer research.

    Amyloid Imaging Taskforce (AIT)

  • A New Research Ini/a/ve Down Syndrome & Alzheimers disease

    ALZHEIMERS ASSOCIATION, LINDA CRNIC INSTITUTE FOR DOWN SYNDROME, AND GLOBAL DOWN SYNDROME

    FOUNDATION LAUNCH NEW RESEARCH GRANTS PROGRAM

    Initial $1.2 million aims to fund research to better treat Alzheimers in people with Down syndrome and the

    general population

  • 5

    The challenge began 100 years ago November 1906: Alois Alzheimer

    presented first case in Germany 51-year-old Auguste D. had

    profound memory loss, confusion, language difficulty, unfounded suspicions about husband and hospital staff

    Her young age made Alzheimer think Auguste had a rare disease associated with middle age

    tangles

    plaques

  • 6

    Normal Alzheimers disease

    Continuum of Alzheimers Disease

    Adapted from Sperling et al. 2011

  • 7 www.alz.org

    The Dominantly Inherited Alzheimer Network (DIAN) Observational Trial

    0.4

    0.6

    0.8

    1

    1.2

    1.4

    -30 -20 -10 0 10 20

    Muta/on Carriers

    Non-Carriers

    Logical Memory Beta-Amyloid Deposition

    Est. Years Before Clinical Onset Est. Years Before Clinical Onset

    0

    5

    10

    15

    20

    -30 -20 -10 0 10 20

    Muta/on Carriers

    Non-Carriers

    Bateman et al. (2012) N Eng J Med 367: 795- 804

  • 8

    DIAN-Trial Unit Alzheimers Association help to initiate the

    trial: $4.2M grant Three simultaneous trials to test potential

    therapies: Gantenerumab (Roche, Monoclonal antibody to AB) Solaneuzumab (Lilly, Monoclonal antibody to AB) TBD

    Adaptive Trial Design Condenses the timeline Trial began March, 2013

  • 9

    Genetic Links to Alzheimers and Down Syndrome

  • 10

    NATURE REVIEWS | DRUG DISCOVERY VOLUME 11 | SEPTEMBER 2012 | 655